— Brings Total Funding to $40.2 Million —- Developing Massively Parallel 10,000-Well Silicon Platform for Commercialization of Synthetic Gene Constructs —

Twist Bioscience today announced that it raised $26 million in a Series B financing to commercialize the company’s semiconductor-based synthetic gene manufacturing process. Nick and Joby Pritzker, through their family’s firm Tao Invest, led the round, with participation from ARCH Venture Partners, Paladin Capital Group, Yuri Milner and additional strategic corporate and venture investors. All existing investors participated in the round.

The company also received a $5.1 million contract from the Defense Advanced Research Projects Agency (DARPA) to fund development of Twist’s technology platform for the large-scale, high-throughput construction of genetic designs. DARPA granted the contract under the Living Foundries: 1000 Molecules Program, which seeks to build a scalable, integrated, rapid design and prototyping infrastructure for the facile engineering of biology.

“In just 10 months, we have established a top tier leadership and development team, created a working prototype of our 10,000-well silicon platform for synthetic DNA production and raised a total of $40.2 million,” said Emily Leproust, Ph.D., chief executive officer of Twist Bioscience. “Today, we have all the necessary components in place to automate and scale our synthetic gene manufacturing process and staff strategically, with the goal of bringing our first products and services to the market in 2015.”

Under the leadership of Emily Leproust, Ph.D., chief executive officer, Bill Banyai, Ph.D., chief operating officer, and Bill Peck, Ph.D., chief technology officer, Twist Bioscience plans to hire 80 employees in the fields of informatics, hardware and software engineering, chemistry, biochemistry, sales and marketing, and operations over the course of the next 18 months.

ABOUT TWIST BIOSCIENCE

At Twist Bioscience, our expertise is synthetic DNA. We have developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. By synthesizing DNA on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic DNA production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. The Twist Bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. For more information, please visit www.twistbioscience.com .

Logo – http://photos.prnewswire.com/prnh/20140526/91128

SOURCE Twist Bioscience